請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73528
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(Yen-Ping Kuo) | |
dc.contributor.author | Sheng-Jiun Shie | en |
dc.contributor.author | 謝昇峻 | zh_TW |
dc.date.accessioned | 2021-06-17T07:40:08Z | - |
dc.date.available | 2019-03-05 | |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-02-15 | |
dc.identifier.citation | 1. Sundqvist, K., et al., Cytotoxic and genotoxic effects of areca nut-related compounds in cultured human buccal epithelial cells. Cancer Res, 1989. 49(19): p. 5294-8.
2. Chang, M.C., et al., Areca nut components stimulate ADAM17, IL-1alpha, PGE2 and 8-isoprostane production in oral keratinocyte: role of reactive oxygen species, EGF and JAK signaling. Oncotarget, 2016. 7(13): p. 16879-94. 3. Yang, S.F., C.H. Tsai, and Y.C. Chang, The upregulation of heat shock protein 47 expression in human buccal fibroblasts stimulated with arecoline. J Oral Pathol Med, 2008. 37(4): p. 206-10. 4. Lin, S.C., et al., Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer, 2005. 116(4): p. 526-35. 5. Chiu, C.C., et al., Betel quid extract promotes oral cancer cell migration by activating a muscarinic M4 receptor-mediated signaling cascade involving SFKs and ERK1/2. Biochem Biophys Res Commun, 2010. 399(1): p. 60-5. 6. Deng, Y.T., et al., Arecoline stimulated Cyr61 production in human gingival epithelial cells: inhibition by lovastatin. Oral Oncol, 2011. 47(4): p. 256-61. 7. Moutasim, K.A., et al., Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol, 2011. 223(3): p. 366-77. 8. Wang, T.Y., et al., Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline. Oncotarget, 2016. 7(51): p. 84072-84081. 9. Shi, W., et al., The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. J Cell Biol, 2000. 148(3): p. 591-602. 10. Black, S.A., Jr., et al., Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem, 2007. 282(21): p. 15416-29. 11. Leask, A., et al., Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem, 2003. 278(15): p. 13008-15. 12. Xie, S., et al., Regulation of TGF-beta 1-induced connective tissue growth factor expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2005. 288(1): p. L68-76. 13. Phanish, M.K., et al., TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol, 2005. 100(4): p. e156-65. 14. Black, S.A., Jr. and P.C. Trackman, Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression. J Biol Chem, 2008. 283(16): p. 10835-47. 15. Chang, Y. and X.Y. Wu, JNK1/2 siRNA inhibits transforming-growth factor-beta1-induced connective tissue growth factor expression and fibrotic function in THSFs. Mol Cell Biochem, 2010. 335(1-2): p. 83-9. 16. Holmes, A., et al., CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem, 2001. 276(14): p. 10594-601. 17. Flanders, K.C., Smad3 as a mediator of the fibrotic response. Int J Exp Pathol, 2004. 85(2): p. 47-64. 18. Yen, E.Y., et al., Exosomal TGF-beta1 is correlated with lymphatic metastasis of gastric cancers. Am J Cancer Res, 2017. 7(11): p. 2199-2208. 19. Kalluri, R. and M. Zeisberg, Fibroblasts in cancer. Nat Rev Cancer, 2006. 6(5): p. 392-401. 20. Kalluri, R., The biology and function of fibroblasts in cancer. Nat Rev Cancer, 2016. 16(9): p. 582-98. 21. Cascione, M., et al., Morphomechanical Alterations Induced by Transforming Growth Factor-beta1 in Epithelial Breast Cancer Cells. Cancers (Basel), 2018. 10(7). 22. Wu, S., et al., Human adiposederived mesenchymal stem cells promote breast cancer MCF7 cell epithelialmesenchymal transition by cross interacting with the TGFbeta/Smad and PI3K/AKT signaling pathways. Mol Med Rep, 2018. 23. Yao, Y., et al., Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-beta signaling in breast cancer. J Exp Clin Cancer Res, 2018. 37(1): p. 282. 24. Quinn, A.M., R.G. Harvey, and T.M. Penning, Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem Res Toxicol, 2008. 21(11): p. 2207-15. 25. Zhang, W., et al., Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway. Cancer Lett, 2014. 355(2): p. 273-80. 26. Cao, E., et al., TRPV1 structures in distinct conformations reveal activation mechanisms. Nature, 2013. 504(7478): p. 113-8. 27. Chen, Y.J., et al., Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol, 2005. 97(1): p. 110-7. 28. Yoshitake, H., et al., Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer, 2007. 17(6): p. 1300-6. 29. Kapoor, S., AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker. Int J Cancer, 2013. 132(2): p. 495. 30. Cao, Z., et al., Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10. Anticancer Drugs, 2014. 25(8): p. 930-7. 31. Matsunaga, T., et al., Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10. Toxicol Appl Pharmacol, 2014. 278(2): p. 180-9. 32. Crosas, B., et al., Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J, 2003. 373(Pt 3): p. 973-9. 33. Gallego, O., et al., Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A, 2007. 104(52): p. 20764-9. 34. Endo, S., et al., Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. Chem Biol Interact, 2011. 191(1-3): p. 261-8. 35. Ma, J., et al., Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem, 2008. 283(6): p. 3418-23. 36. Matsunaga, T., et al., Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers. Front Pharmacol, 2012. 3: p. 5. 37. Ohashi, T., et al., AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res, 2013. 11(12): p. 1554-63. 38. Fukumoto, S., et al., Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res, 2005. 11(5): p. 1776-85. 39. Kang, M.W., et al., AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res, 2011. 39(1): p. 78-85. 40. Ma, J., et al., AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int J Cancer, 2012. 131(6): p. E862-71. 41. Matkowskyj, K.A., et al., Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol, 2014. 45(4): p. 834-43. 42. Chung, Y.T., et al., Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod Pathol, 2012. 25(5): p. 758-66. 43. Li, H., et al., Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). Carcinogenesis, 2013. 34(9): p. 2090-8. 44. Mashima, T., et al., Apoptosis resistance in tumor cells. Cytotechnology, 1998. 27(1-3): p. 293-308. 45. Dickinson, B.C. and C.J. Chang, Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol, 2011. 7(8): p. 504-11. 46. Gupta, S.C., et al., Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal, 2012. 16(11): p. 1295-322. 47. Muller, F., The nature and mechanism of superoxide production by the electron transport chain: Its relevance to aging. J Am Aging Assoc, 2000. 23(4): p. 227-53. 48. Han, D., E. Williams, and E. Cadenas, Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J, 2001. 353(Pt 2): p. 411-6. 49. Li, X., et al., Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol, 2013. 6: p. 19. 50. Curtin, J.F., M. Donovan, and T.G. Cotter, Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods, 2002. 265(1-2): p. 49-72. 51. Durrigl, T., et al., Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. J Int Med Res, 1975. 3(3): p. 139-44. 52. Ku, E.C., J.M. Wasvary, and W.D. Cash, Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochem Pharmacol, 1975. 24(5): p. 641-3. 53. Endo, S., et al., Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull, 2010. 33(5): p. 886-90. 54. Gobec, S., P. Brozic, and T.L. Rizner, Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. Bioorg Med Chem Lett, 2005. 15(23): p. 5170-5. 55. Ziberna, L., et al., Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy. Int J Mol Sci, 2017. 18(3). 56. Ayeleso, T.B., M.G. Matumba, and E. Mukwevho, Oleanolic Acid and Its Derivatives: Biological Activities and Therapeutic Potential in Chronic Diseases. Molecules, 2017. 22(11). 57. Takemura, M., et al., Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. J Nat Prod, 2011. 74(5): p. 1201-6. 58. Matsunaga, T., et al., Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-gamma-dependent mechanism. Chem Biol Interact, 2016. 256: p. 142-53. 59. Srivastava, K.C., A. Bordia, and S.K. Verma, Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids, 1995. 52(4): p. 223-7. 60. Choi, H., et al., Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol, 2006. 70(5): p. 1664-71. 61. Aggarwal, B.B. and S. Shishodia, Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 2006. 71(10): p. 1397-421. 62. Matsunaga, T., et al., Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs, 2011. 22(5): p. 402-8. 63. Endo, S., et al., Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells. J Med Chem, 2017. 60(20): p. 8441-8455. 64. Sell, S., Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect, 1993. 101 Suppl 5: p. 15-26. 65. Kuo, M.Y., et al., Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med, 1995. 24(6): p. 255-60. 66. Liu, W., et al., Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med, 2009. 15(5): p. 559-65. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73528 | - |
dc.description.abstract | 根據衛服部2017年統計,口腔癌在臺灣癌症十大死因中排名第四位。在口腔癌早期(I-II期)治療成功率相當高,但有仍然有30%的病患有復發的情形;對於口腔癌晚期的患者,即便目前化療和放療日益進步,其治療成功率也仍低於30%,而近20年間,口腔癌患者的五年存活率依舊沒有變化,因此需要繼續找尋新的診斷標誌以及標靶藥物。
我們研究發現檳榔中的主要成分檳榔鹼Arecoline可以誘導口腔癌SAS和Ca9-22細胞株中AKR1B10蛋白大量表現,我們嘗試找尋可能的訊息傳導途徑,其中包含了TGF-β1路徑,結果在SAS和Ca9-22細胞株中發現TGF-β1中和抗體和ALK5 抑制劑 (SB431542) 以及 Smad3 抑制劑 (SIS3)可以降低AKR1B10蛋白表現量,接著我們利用TGF-β1誘導SAS細胞株中AKR1B10大量表現,經由抑制劑發現路徑有PI3K、ERK、JNK以及Src;此外我們也發現薑黃素能夠抑制經由Arecoline所誘導的AKR1B10的蛋白質表現量。 我們探討AKR1B10與化療抗性中所扮演的角色,結果發現在內生性AKR1B10蛋白大量表現的HSC3細胞株中,加入AKR1B10蛋白抑制劑Dicofenac可以提高化療藥物CDDP對口腔癌SAS細胞株的毒性。 關鍵字: 檳榔鹼、口腔癌、醛酮還原酶1B10、活性氧(ROS)、薑黃素、轉化生長因子-β1 | zh_TW |
dc.description.abstract | In Taiwan, oral cancer is the sixth leading cause of death from cancer in both genders and ranks the fourth in males in 2011. Although treatment of early stage oral cancer (stage I or II) is frequently successful, disease relapses still occur in about 30% patient. For patients with advanced disease, fewer than 30% of them can be cured. Despite recent advances in surgery, radiotherapy and chemotherapy, the overall 5-year survival rate for patients with oral cancer has not changed during the past two decades. Thererfore, continued investigation of new diagnostic markers and chemotherapeutic agents is needed.
We found Aldo-keto reductase 1B10 (AKR1B10) is induced by an areca nut alkaloid, arecoline. Arecoline induce AKR1B10 synthesis in a dose- and time- depend Manner in SAS and Ca9-22 cell. We aimed to examine the possible signal transduction pathways involved in TGF-β1-induced AKR1B10 expression in SAS and Ca9-22 cell, we found the effect that Arecoline induces AKR1B10 activation was inhibited by TGF-β1 neutralizing antibody, ALK5 inhibitor (SB431542) and Smad3 inhibitor (SIS3).We have also shown that PI3K inhibitor (LY294002), ERK inhibitor (PD98059), JNK inhibitor (SP600125), and Src inhibitor (PP2) are involved in the TGF-β1-induced AKR1B10 in SAS cell.Furthermore, Cucurmin completely inhibited Arecoline-induced AKR1B10 synthesis and inhibition is dose-dependent. We investigate whether AKR1B10 play a role in regulating chemoresistant in SAS cells. We found inhibited AKR1B10 significantly inhibited chemoresistant in HSC3 cell. KEYWORDS: Arecoline、oral cancer、Aldo-keto reductase 1B10,AKR1B10、Reactive oxygen species (ROS)、Curcumin、Transforming growth factor-β1 | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:40:08Z (GMT). No. of bitstreams: 1 ntu-108-R05450016-1.pdf: 2139512 bytes, checksum: 50cf20064c3a9a65080f6a863300032d (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員審定書…………………………………………………………………………………#
誌謝 i 中文摘要 ii Abstract iii 第一章 導論 1 第一節 口腔癌 1 1.1.1. 口腔癌的簡介 1 1.1.2. 檳榔與口腔癌症 2 第二節 檳榔鹼(Arecoline) 3 1.2.1. Arecoline與口腔癌 3 第三節 轉化生長因子(Transforming growth factor-β1,TGF-β1) 4 1.3.1. TGF-β的結構 4 1.3.2. TGF-β1的訊息傳遞路徑 5 1.3.3. TGF-β1與癌症 6 第四節 醛酮還原酶家族(Aldo-keto reductase family) 6 1.4.1. 醛酮還原酶家族 6 1.4.2. 醛酮還原酶1B10(Aldo-keto reductase 1B10,AKR1B10)簡介 7 1.4.3. AKR1B10與癌症 9 第五節 活性氧化物(Reactive oxygen species,ROS) 11 1.5.1. ROS的簡介 11 1.5.2. ROS與癌症 11 1.5.3. 內源性ROS 11 第六節 雙氯芬酸鈉 (Diclofenac soudium) 12 第七節 齊墩果酸 (Olenoid acid) 13 第八節 薑黃素(Curcumin) 13 第二章 實驗目的 15 第三章 材料與方法 16 第一節 細胞株與細胞培養 16 3.1.1. 細胞株的培養 16 3.1.2. 繼代培養 16 第二節 藥物處理 16 3.2.1. 種細胞以及starvation 16 3.2.2. 抑制劑、抗氧化劑以及中和抗體使用資料 17 3.2.3. Arecoline、TGF-β1以及其他藥物使用資料 18 第三節 西方墨點法(Western blot) 18 3.3.1. 蛋白質萃取 18 3.3.2. 配置膠體 19 3.3.3. 電泳分析 19 3.3.4. 蛋白質的轉漬 19 3.3.5. 抗體的使用 20 3.3.6. 顯影呈色 20 第四節 (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)(MTT) 20 3.4.1. MTT試劑 20 3.4.2. 吸光值測量 21 第五節 Enzyme-linked immunosorbent assay(ELISA) 21 3.5.1. Coating 21 3.5.2. Blocking 21 3.5.3. Sample & standard 22 3.5.4. Detection 22 3.5.5. Streptavidin-HRP 22 3.5.6. TMB substrate 22 3.5.7. Stop reaction & read OD value 22 第六節 統計分析 23 第四章 結果 24 Arecoline誘導Ca9-22和SAS細胞AKR1B10蛋白質表現 24 Arecoline經由TGF-β路徑誘導Ca9-22和SAS細胞AKR1B10蛋白質表現 24 Arecoline可誘導SAS細胞釋出活化態TGF-β1 24 TGF-β1誘導SAS細胞AKR1B10蛋白質表 25 PI3K、ERK、JNK以及Src調控TGF-β1誘導SAS細胞AKR1B10蛋白質表現25 Curcumin抑制Arecoline誘導SAS細胞AKR1B10蛋白質表現 25 Diclofenac可增加HSC3細胞株對化療藥物CDDP的敏感度 26 Oleanolic acid無法增加HSC3細胞株對化療藥物CDDP的敏感度 26 第五章 討論 27 第六章 圖與表 32 參考文獻 47 | |
dc.language.iso | zh-TW | |
dc.title | Arecoline誘導口腔癌上皮細胞AKR1B10表現的訊息傳遞路徑 | zh_TW |
dc.title | Signal transduction pathways of arecoline-induced AKR1B10 expression in oral epithelial cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周涵怡(Han-Yi Chou),張瑞青(RUEI-CING JHANG) | |
dc.subject.keyword | 醛酮還原?1B10,轉化生長因子,薑黃素,活性氧化物,口腔癌,檳榔鹼, | zh_TW |
dc.subject.keyword | Arecoline,Aldo-keto reductase 1B10,Transforming growth factor-β1,oral cancer,Curcumin,Reactive oxygen species (ROS), | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU201900468 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-02-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。